Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient's follow‐up - Université Sorbonne Paris Nord Accéder directement au contenu
Article Dans Une Revue Clinical Pharmacology and Therapeutics Année : 2019

Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient's follow‐up

Résumé

We characterized the association between tumor size kinetics and survival in advanced urothelial cancer patients treated with atezolizumab (anti-programmed death-ligand 1 (PD-L1), Tecentriq) using a joint model. The model, developed on data from 309 patients of a phase 2 clinical trial, identified the time-to-tumor growth and the instantaneous changes in tumor size as the best on-treatment predictors of survival. On the validation dataset containing data from 457 patients from a phase 3 study, the model predicted individual survival probability using 3 or 6-months tumor size follow-up data with an area under the receptor-occupancy curve between 0.75 and 0.84 as compared to values comprised between 0.62 and 0.75 when the model included only information available at treatment initiation. Including tumor size kinetics in a relevant statistical framework improve the prediction of survival probability during immunotherapy treatment, and may be useful to identify most-at-risk patients in "real-time". This article is protected by copyright. All rights reserved.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-02103513 , version 1 (18-04-2019)

Identifiants

Citer

Coralie Tardivon, Solène Desmée, Marion Kerioui, René Bruno, Benjamin Wu, et al.. Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient's follow‐up. Clinical Pharmacology and Therapeutics, inPress, Epub ahead of print. ⟨10.1002/cpt.1450⟩. ⟨inserm-02103513⟩
222 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More